TransMedics Group (NASDAQ:TMDX – Get Free Report) had its price target increased by stock analysts at Stifel Nicolaus from $70.00 to $80.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “hold” rating on the stock. Stifel Nicolaus‘s price objective indicates a potential downside of 14.91% from the stock’s current price.
A number of other analysts have also recently commented on TMDX. Zacks Research upgraded shares of TransMedics Group from a “strong sell” rating to a “hold” rating in a research note on Monday, November 2nd. Canaccord Genuity Group raised their price target on TransMedics Group from $95.00 to $120.00 and gave the company a “buy” rating in a report on Friday, November 6th. Wall Street Zen upgraded shares of TransMedics Group from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Needham & Company LLC increased their price objective on shares of TransMedics Group from $106.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Finally, Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Five analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group currently has an average rating of “Hold” and an average target price of $113.30.
View Our Latest Research Report on TMDX
TransMedics Group Trading Down 2.5%
TransMedics Group stock opened at $94.02 on Friday. The firm has a 50-day moving average of $80.82 and a 200-day moving average of $91.19. TransMedics Group has a one year low of $60.10 and a one year high of $156.00. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.53 and a quick ratio of 4.15. The company has a market cap of $3.27 billion, a price-to-earnings ratio of 52.98, a P/E/G ratio of 1.71 and a beta of 2.14.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The business had revenue of $203.01 million for the quarter, compared to the consensus estimate of $178.06 million. During the same quarter in the previous year, the business earned $0.66 earnings per share. TransMedics Group’s quarterly revenue was up 41.1% on a year-over-year basis. On average, equities analysts expect that TransMedics Group will post 1.66 earnings per share for the current fiscal year.
Insider Activity
In other TransMedics Group news, Director David Weill purchased 1,336 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the purchase, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.
Institutional Trading of TransMedics Group
A number of institutional investors have recently bought and sold shares of the business. Silvant Capital Management LLC bought a new position in shares of TransMedics Group during the second quarter worth approximately $26,000. State of Wyoming acquired a new stake in TransMedics Group during the second quarter worth approximately $31,000. Ancora Advisors LLC bought a new position in TransMedics Group during the 2nd quarter worth $33,000. Persistent Asset Partners Ltd bought a new position in TransMedics Group during the 2nd quarter worth $55,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in TransMedics Group by 700.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 800 shares of the company’s stock valued at $67,000 after acquiring an additional 700 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.
TransMedics Group Company Profile
TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.
See Also
- Five stocks we like better than TransMedics Group
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
